针对骨髓移植病患中铁过载的去铁治疗研究进展

doi:10.16288/j.yczz.15-195

遗传 ›› 2015, Vol. 37 ›› Issue (9): 865-872.doi: 10.16288/j.yczz.15-195

针对骨髓移植病患中铁过载的去铁治疗研究进展

李士伟¹, 李想², 关锋¹

1. 江南大学生物工程学院,无锡 214122;
2. 江南大学无锡医学院,无锡 214122

收稿日期:2015-05-06 修回日期:2015-07-22 出版日期:2015-09-20 发布日期:2015-09-20
通讯作者: 李想,博士,副教授,研究方向：骨髓微环境对造血干细胞的发育以及分化的影响。E-mail: xiangli@jiangnan.edu.cn
关锋,博士,教授,研究方向：糖生物学研究。E-mail: fengguan@jiangnan.edu.cn
作者简介:李士伟,博士生,专业方向：生物制药。E-mail: 289920680@qq.con
基金资助:
国家自然科学基金面上项目（编号：81470294）资助

Progress of iron-chelating therapy for iron overload in patients after bone marrow transplantation

Shiwei Li¹, Xiang Li², Feng Guan¹

1. School of Biotechnology, Jiangnan University, Wuxi 214122, China;
2.Wuxi Medical School, Jiangnan University, Wuxi 214122, China

Received:2015-05-06 Revised:2015-07-22 Online:2015-09-20 Published:2015-09-20

摘要/Abstract

摘要： 骨髓移植是临床上治疗恶性造血系统疾病的常见手段。而铁过载是临床上常见的并发症之一,对病患的造血功能和治疗后恢复有极大的抑制作用。了解铁过载产生的分子或遗传机制能帮助优化去铁化方案,提高去铁化治疗的效率。本文总结了骨髓移植前后铁过载现象发生机制的最新研究进展,并阐述了临床上多种去铁治疗的方案,以期为该类病患铁过载的预防和治疗提供参考。

关键词: 骨髓移植, 铁过载, 去铁治疗

Abstract: Bone marrow transplantation (BMT) is commonly used to treat hematopoietic system malignant diseases. Iron overload, which is one of the most common complications in patients undergoing BMT, has a negative impact on survival after allogeneic transplantation. Better understanding of molecular mechanisms of iron overload can improve the treatment regime and improve the efficiency for iron-chelating therapy. In this review, we summarize the mechanisms of iron overload in various conditions and the progression of iron-chelating strategies in patients undergoing BMT. This review will provide insights into the prevention and treatment of patients with iron overload after BMT.

Key words: bone marrow transplantation, iron overload, iron-chelating therapy

李士伟, 李想, 关锋. 针对骨髓移植病患中铁过载的去铁治疗研究进展[J]. 遗传, 2015, 37(9): 865-872.

Shiwei Li, Xiang Li, Feng Guan. Progress of iron-chelating therapy for iron overload in patients after bone marrow transplantation[J]. HEREDITAS(Beijing), 2015, 37(9): 865-872.

参考文献

[1] Bystrom LM, Guzman ML, Rivella S. Iron and reactive oxygen species: friends or foes of cancer cells?. Antioxid Redox Sign , 2014, 20(12): 1917-1924.
[2] Estevão IF, Junior PP, Bonini-Domingos CR. Serum ferritin and transferrin saturation levels in β 0 and β + thalassemia patients. Genet Mol Res , 2011, 10(2): 632-639.
[3] Galano A, Medina ME, Tan DX, Reiter RJ. Melatonin and its metabolites as copper chelating agents and their role in inhibiting oxidative stress: a physicochemical analysis. J Pineal Res , 2015, 58(1): 107-116.
[4] McKay PJ, Murphy JA, Cameron S, Burnett AK, Campbell M, Tansey P, Franklin IM. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant , 1996, 17(1): 63-66.
[5] Ali S, Pimentel JD, Munoz J, Shah V, McKinnon R, Divine G, Janakiraman N. Iron overload in allogeneic hematopoietic stem cell transplant recipients. Arch Pathol Laborat Med , 2012, 136(5): 532-538.
[6] Trottier BJ, Burns LJ, DeFor TE, Cooley S, Majhail NS. Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. Blood , 2013, 122(9): 1678-1684.
[7] Gordon LI, Brown SG, Tallman MS, Rademaker AW, Weitzman SA, Lazarus HM, Kelley CH, Mangan C, Rubin H, Fox RM, Creger RJ, Winter JN. Sequential changes in serum iron and ferritin in patients undergoing high-dose chemotherapy and radiation with autologous bone marrow transplantation: Possible implications for treatment related toxicity. Free Rad Biol Med , 1995, 18(3): 383-389.
[8] Meyer SC, O’Meara A, Buser AS, Tichelli A, Passweg JR, Stern M. Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation. Biol Blood Marrow Tr , 2013, 19(3): 440-444.
[9] Busca A, Dellacasa C, Pecoraro C. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation. Global J Hematol Blo , 2014, 1: 6-17.
[10] Sivgin S, Eser B. The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: Where do we stand?. Ann Hematol , 2013, 92(5): 577-586.
[11] Muckenthaler MU. Red Cells, Iron, & Erythropoiesis: How mutant HFE causes hereditary hemochromatosis. Blood , 2014, 124(8): 1212.
[12] de Witte T. The role of iron in patients after bone marrow transplantation. Blood Rev , 2008, 22(Suppl. 2): S22-S28.
[13] Chua K, Fung E, Micewicz ED, Ganz T, Nemeth E, Ruchala P. Small cyclic agonists of iron regulatory hormone hepcidin. Bioorg Med Chem Lett , 2015, doi:10.1016/j.bmcl.2015.03.012.
[14] Sucak GT, Yaşar DG, Yegin ZA, Ergün MA, Özkurt ZN, Akı ŞZ, Güntekin S. The prognostic role of hemochromatosis H63D allele in allogeneic hematopoietic stem cell transplantation. Ann Hematol , 2012, 91(8): 1281-1287.
[15] Kaczorowska-Hac B, Szalewska M, Niedzwiecki M, Adamkiewicz-Drozynska E, Milosz E. Iron overload in two children after allogeneic hematopoietic SCT with concomitant HFE p.s65cgene mutation. J Blood Lymph , 2014, 4(1): 1000117.
[16] Finch C. Regulators of iron balance in humans. Blood , 1994, 84(6): 1697-1702.
[17] Liu QD, Davidoff O, Niss K, Haase VH. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest , 2012, 122(12): 4635.
[18] Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NLC, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med , 2007, 13(9): 1096-1101.
[19] Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, Lee YT, Goodnough JB, Harandi O, Ganz T, Paulson RF, Miller JL. Identi

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

针对骨髓移植病患中铁过载的去铁治疗研究进展

Progress of iron-chelating therapy for iron overload in patients after bone marrow transplantation

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics